<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>dataFromDDI</source><date>13/09/2017</date><key>2</key><document><id>DDI-MedLine.d111</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro.&#xd;
The effects of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro was investigated. Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. To each preparation was added one additional drug at three concentrations ranging from therapeutic to toxic. The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital. acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. Each serum without the other added drug as well as the serum supplemented with the other drug at the three concentrations was dialyzed against phosphate buffer. Similarly dialyzed were phenobarbital, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. The percentage of drug binding in each preparation was calculated. Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; phenobarbital reduced it by a net change of 6.6% (percentage increase in FDF, 8.5%) at 431 micromol/L. Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. No significant effects were noted with other drug combinations or with the addition of ethanol. Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. The resulting increase in free drug concentration may lead to enhanced drug effect in vivo.</text><annotation id="DDI-MedLine.d111.s0.e0"><infon key="type">drug</infon><location offset="35" length="7"/><text>ethanol</text></annotation><annotation id="DDI-MedLine.d111.s1.e0"><infon key="type">drug</infon><location offset="145" length="7"/><text>ethanol</text></annotation><annotation id="DDI-MedLine.d111.s2.e0"><infon key="type">drug</infon><location offset="231" length="13"/><text>Acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s2.e1"><infon key="type">drug</infon><location offset="246" length="9"/><text>lidocaine</text></annotation><annotation id="DDI-MedLine.d111.s2.e2"><infon key="type">drug</infon><location offset="257" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s2.e3"><infon key="type">drug</infon><location offset="272" length="9"/><text>quinidine</text></annotation><annotation id="DDI-MedLine.d111.s2.e4"><infon key="type">drug</infon><location offset="283" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d111.s2.e5"><infon key="type">drug</infon><location offset="301" length="13"/><text>valproic acid</text></annotation><annotation id="DDI-MedLine.d111.s4.e0"><infon key="type">drug</infon><location offset="558" length="13"/><text>acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s4.e1"><infon key="type">drug</infon><location offset="572" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s5.e0"><infon key="type">drug</infon><location offset="587" length="13"/><text>acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s5.e1"><infon key="type">drug</infon><location offset="601" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d111.s5.e2"><infon key="type">drug</infon><location offset="615" length="9"/><text>lidocaine</text></annotation><annotation id="DDI-MedLine.d111.s5.e3"><infon key="type">drug</infon><location offset="625" length="9"/><text>quinidine</text></annotation><annotation id="DDI-MedLine.d111.s5.e4"><infon key="type">drug</infon><location offset="636" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s5.e5"><infon key="type">drug</infon><location offset="650" length="13"/><text>acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s5.e6"><infon key="type">drug</infon><location offset="665" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s5.e7"><infon key="type">drug</infon><location offset="679" length="13"/><text>valproic acid</text></annotation><annotation id="DDI-MedLine.d111.s5.e8"><infon key="type">drug</infon><location offset="694" length="9"/><text>quinidine</text></annotation><annotation id="DDI-MedLine.d111.s5.e9"><infon key="type">drug</infon><location offset="704" length="9"/><text>lidocaine</text></annotation><annotation id="DDI-MedLine.d111.s5.e10"><infon key="type">drug</infon><location offset="715" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d111.s5.e11"><infon key="type">drug</infon><location offset="728" length="13"/><text>acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s5.e12"><infon key="type">drug</infon><location offset="747" length="13"/><text>valproic acid</text></annotation><annotation id="DDI-MedLine.d111.s5.e13"><infon key="type">drug</infon><location offset="761" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s7.e0"><infon key="type">drug</infon><location offset="961" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s7.e1"><infon key="type">drug</infon><location offset="976" length="9"/><text>quinidine</text></annotation><annotation id="DDI-MedLine.d111.s7.e2"><infon key="type">drug</infon><location offset="991" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d111.s7.e3"><infon key="type">drug</infon><location offset="1064" length="7"/><text>ethanol</text></annotation><annotation id="DDI-MedLine.d111.s9.e0"><infon key="type">drug</infon><location offset="1183" length="13"/><text>Acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s9.e1"><infon key="type">drug</infon><location offset="1223" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d111.s10.e0"><infon key="type">drug</infon><location offset="1434" length="12"/><text>Theophylline</text></annotation><annotation id="DDI-MedLine.d111.s10.e1"><infon key="type">drug</infon><location offset="1472" length="13"/><text>acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s11.e0"><infon key="type">drug</infon><location offset="1566" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s12.e0"><infon key="type">drug</infon><location offset="1669" length="13"/><text>Valproic acid</text></annotation><annotation id="DDI-MedLine.d111.s12.e1"><infon key="type">drug</infon><location offset="1705" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s13.e0"><infon key="type">drug</infon><location offset="1886" length="7"/><text>ethanol</text></annotation><annotation id="DDI-MedLine.d111.s14.e0"><infon key="type">drug</infon><location offset="1910" length="13"/><text>acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s14.e1"><infon key="type">drug</infon><location offset="1929" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d111.s14.e2"><infon key="type">drug</infon><location offset="1943" length="13"/><text>phenobarbital</text></annotation><annotation id="DDI-MedLine.d111.s14.e3"><infon key="type">drug</infon><location offset="1962" length="13"/><text>acetaminophen</text></annotation><annotation id="DDI-MedLine.d111.s14.e4"><infon key="type">drug</infon><location offset="1981" length="13"/><text>valproic acid</text></annotation><annotation id="DDI-MedLine.d111.s14.e5"><infon key="type">drug</infon><location offset="2000" length="13"/><text>phenobarbital</text></annotation></passage></document><document><id>DDI-MedLine.d70</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Toxicity of cadmium and zinc to miracidia of Schistosoma mansoni.
The specific objectives of this study were to elucidate metal toxicity to hatching, survival and avoidance behaviour of Schistosoma mansoni miracidia. The toxicity of cadmium, zinc, and cadmium/zinc mixtures at concentrations ranging from 10000 to 10 microg/l was investigated. Metal mixture toxicity investigation was undertaken with equal concentrations of the metals. The hatching of miracidia from eggs was inhibited by concentrations of 1000-10000 microg/l of single metals. Metal mixtures had no effect on egg hatching. Survival of miracidia was reduced by increasing metal concentration except at concentrations of 10 microg/l for single metal toxicity where survival was increased above the control. Miracidia demonstrated a rapid avoidance behaviour when briefly exposed to heavy metals. The mechanisms of metal toxicity to miracidia are briefly discussed.</text><annotation id="DDI-MedLine.d70.s0.e0"><infon key="type">drug</infon><location offset="24" length="4"/><text>zinc</text></annotation><annotation id="DDI-MedLine.d70.s2.e0"><infon key="type">drug</infon><location offset="242" length="4"/><text>zinc</text></annotation><annotation id="DDI-MedLine.d70.s5.e0"><infon key="type">drug</infon><location offset="578" length="3"/><text>egg</text></annotation></passage></document><document><id>DDI-MedLine.d79</id><passage><infon key="type">abstract</infon><offset>0</offset><text>If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.&#xd;
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. Median gastric pH was significantly higher when indinavir was taken after didanosine administration; however, no significant difference in the maximum concentration in plasma or the area under the concentration-time curve from time zero to 8 h was observed. Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.</text><annotation id="DDI-MedLine.d79.s0.e0"><infon key="type">drug</infon><location offset="23" length="9"/><text>indinavir</text></annotation><annotation id="DDI-MedLine.d79.s0.e1"><infon key="type">drug</infon><location offset="34" length="3"/><text>IDV</text></annotation><annotation id="DDI-MedLine.d79.s0.e2"><infon key="type">drug</infon><location offset="40" length="10"/><text>didanosine</text></annotation><annotation id="DDI-MedLine.d79.s0.e3"><infon key="type">drug</infon><location offset="67" length="3"/><text>IDV</text></annotation><annotation id="DDI-MedLine.d79.s1.e0"><infon key="type">drug</infon><location offset="149" length="9"/><text>indinavir</text></annotation><annotation id="DDI-MedLine.d79.s1.e1"><infon key="type">drug</infon><location offset="163" length="10"/><text>didanosine</text></annotation><annotation id="DDI-MedLine.d79.s1.e2"><infon key="type">drug</infon><location offset="221" length="9"/><text>indinavir</text></annotation><annotation id="DDI-MedLine.d79.s1.e3"><infon key="type">drug</infon><location offset="265" length="10"/><text>didanosine</text></annotation><annotation id="DDI-MedLine.d79.s1.e4"><infon key="type">drug</infon><location offset="291" length="9"/><text>indinavir</text></annotation><annotation id="DDI-MedLine.d79.s2.e0"><infon key="type">drug</infon><location offset="334" length="9"/><text>indinavir</text></annotation><annotation id="DDI-MedLine.d79.s2.e1"><infon key="type">drug</infon><location offset="449" length="9"/><text>indinavir</text></annotation><annotation id="DDI-MedLine.d79.s2.e2"><infon key="type">drug</infon><location offset="482" length="9"/><text>indinavir</text></annotation><annotation id="DDI-MedLine.d79.s2.e3"><infon key="type">drug</infon><location offset="515" length="10"/><text>didanosine</text></annotation><annotation id="DDI-MedLine.d79.s3.e0"><infon key="type">drug</infon><location offset="590" length="9"/><text>indinavir</text></annotation><annotation id="DDI-MedLine.d79.s3.e1"><infon key="type">drug</infon><location offset="616" length="10"/><text>didanosine</text></annotation><annotation id="DDI-MedLine.d79.s5.e0"><infon key="type">drug</infon><location offset="800" length="9"/><text>Indinavir</text></annotation><annotation id="DDI-MedLine.d79.s5.e1"><infon key="type">drug</infon><location offset="887" length="10"/><text>didanosine</text></annotation></passage></document><document><id>DDI-MedLine.d45</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts.&#xd;
The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine was evaluated as a possible explanation for the association of deep-seated infection with this organism and abuse of these drugs. The mean reduction of growth caused by the drugs was 1,000-fold greater for 49 Pseudomonas strains from normal subjects than for 32 strains from drug addicts (4.2 vs. 1.3 logs of reduction at 2 hr, P less than .0005). A common phenotypic subset of the serotype O11 strains from drug addicts was especially resistant to the inhibitory effects. Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. We conclude that an ability of some P. aeruginosa serotype O11 strains, but not S. aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S. aureus to P. aeruginosa as common pathogens of drug addicts in areas where abuse of this combination of drugs has increased.</text><annotation id="DDI-MedLine.d45.s0.e0"><infon key="type">drug</infon><location offset="22" length="11"/><text>pentazocine</text></annotation><annotation id="DDI-MedLine.d45.s0.e1"><infon key="type">drug</infon><location offset="38" length="14"/><text>tripelennamine</text></annotation><annotation id="DDI-MedLine.d45.s1.e0"><infon key="type">drug</infon><location offset="180" length="11"/><text>pentazocine</text></annotation><annotation id="DDI-MedLine.d45.s1.e1"><infon key="type">drug</infon><location offset="196" length="14"/><text>tripelennamine</text></annotation><annotation id="DDI-MedLine.d45.s5.e1"><infon key="type">drug</infon><location offset="777" length="11"/><text>pentazocine</text></annotation><annotation id="DDI-MedLine.d45.s5.e2"><infon key="type">drug</infon><location offset="793" length="14"/><text>tripelennamine</text></annotation><annotation id="DDI-MedLine.d45.s6.e0"><infon key="type">drug</infon><location offset="974" length="14"/><text>tripelennamine</text></annotation><annotation id="DDI-MedLine.d45.s6.e1"><infon key="type">drug</infon><location offset="1069" length="11"/><text>pentazocine</text></annotation><annotation id="DDI-MedLine.d45.s9.e0"><infon key="type">drug</infon><location offset="1187" length="11"/><text>pentazocine</text></annotation><annotation id="DDI-MedLine.d45.s9.e1"><infon key="type">drug</infon><location offset="1203" length="14"/><text>tripelennamine</text></annotation></passage></document><document><id>DDI-MedLine.d94</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Evidence for reduction of norepinephrine uptake sites in the failing human heart.&#xd;
OBJECTIVES. This study investigated the role of neuronal uptake of norepinephrine (uptake-1) in human heart failure as a local factor for altering concentrations of norepinephrine at the cardiac myocyte membranes. BACKGROUND. Several beta-adrenergic neuroeffector defects occur in heart failure. Whether an alteration in norepinephrine uptake-1 occurs is still unresolved. METHODS. The role of norepinephrine uptake-1 was studied in electrically stimulated (1 Hz, 37 degrees C) human ventricular cardiac preparations and isolated myocardial membranes. RESULTS. The effectiveness of norepinephrine in increasing the force of contraction was decreased in relation to the degree of heart failure. In contrast, the potency of norepinephrine was increased in failing hearts (New York Heart Association functional class IV) in relation to the concentrations producing 50% of the maximal effect (EC50). The EC50 values for isoproterenol, which is not a substrate for norepinephrine uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p &lt; 0.05) but not in functional class IV myocardium. Radioligand binding experiments using the uptake inhibitor hydrogen-3 mazindol revealed a significant decrease by approximately 30% in norepinephrine uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p &lt; 0.05). CONCLUSIONS. In human heart failure, there is a presynaptic defect in the sympathetic nervous system, leading to reduced uptake-1 activity. This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as cocaine and desipramine, in the nonfailing heart only. Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. The pathophysiologic consequences could be an increased synaptic concentration of norepinephrine predisposing to adenylyl cyclase desensitization.</text><annotation id="DDI-MedLine.d94.s0.e0"><infon key="type">drug</infon><location offset="26" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s2.e0"><infon key="type">drug</infon><location offset="150" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s5.e0"><infon key="type">drug</infon><location offset="404" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s7.e0"><infon key="type">drug</infon><location offset="477" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s9.e0"><infon key="type">drug</infon><location offset="665" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s10.e0"><infon key="type">drug</infon><location offset="805" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s11.e0"><infon key="type">drug</infon><location offset="999" length="13"/><text>isoproterenol</text></annotation><annotation id="DDI-MedLine.d94.s11.e1"><infon key="type">drug</infon><location offset="1043" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s12.e0"><infon key="type">drug</infon><location offset="1202" length="7"/><text>cocaine</text></annotation><annotation id="DDI-MedLine.d94.s12.e1"><infon key="type">drug</infon><location offset="1214" length="11"/><text>desipramine</text></annotation><annotation id="DDI-MedLine.d94.s12.e2"><infon key="type">drug</infon><location offset="1288" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s13.e0"><infon key="type">drug</infon><location offset="1452" length="8"/><text>mazindol</text></annotation><annotation id="DDI-MedLine.d94.s13.e1"><infon key="type">drug</infon><location offset="1517" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s16.e0"><infon key="type">drug</infon><location offset="1887" length="7"/><text>cocaine</text></annotation><annotation id="DDI-MedLine.d94.s16.e1"><infon key="type">drug</infon><location offset="1899" length="11"/><text>desipramine</text></annotation><annotation id="DDI-MedLine.d94.s17.e0"><infon key="type">drug</infon><location offset="1954" length="14"/><text>norepinephrine</text></annotation><annotation id="DDI-MedLine.d94.s17.e1"><infon key="type">drug</infon><location offset="2032" length="7"/><text>cocaine</text></annotation><annotation id="DDI-MedLine.d94.s17.e2"><infon key="type">drug</infon><location offset="2044" length="11"/><text>desipramine</text></annotation><annotation id="DDI-MedLine.d94.s18.e0"><infon key="type">drug</infon><location offset="2139" length="14"/><text>norepinephrine</text></annotation></passage></document><document><id>DDI-MedLine.d89</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.&#xd;
Gentamicin is an aminoglycoside antibiotic used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys. Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. The presence of the radiopharmaceutical in the kidneys, along with an increase in renal retention, tend to produce scintigraphic results that falsely identify characteristics related to diseases such as renal vascular, or urinary tract obstruction, and even renal cancer. An altered biodistribution may provide misleading information that can either mask or mimic certain disease symptoms. A method to maximize the therapeutic benefit of gentamicin while minimizing the risk of nephrotoxicity and the appearance of a hot kidney on scintigraphy is desirable. Serial pharmacokinetic dosing has been proposed as a method to accomplish this goal. Therapeutic drug monitoring (TDM) of gentamicin therapy, and bone scintigraphy employing 99mTc-MDP as the radiopharmaceutical was carried out in 22 patients. The data presented here demonstrate that with serial pharmacokinetic dosing of gentamicin, the iatrogenic alteration caused by gentamicin therapy can be avoided.</text><annotation id="DDI-MedLine.d89.s0.e0"><infon key="type">drug</infon><location offset="71" length="29"/><text>99mTc-methylene diphosphonate</text></annotation><annotation id="DDI-MedLine.d89.s0.e1"><infon key="type">drug</infon><location offset="107" length="10"/><text>gentamicin</text></annotation><annotation id="DDI-MedLine.d89.s1.e0"><infon key="type">drug</infon><location offset="132" length="10"/><text>Gentamicin</text></annotation><annotation id="DDI-MedLine.d89.s2.e0"><infon key="type">drug</infon><location offset="324" length="10"/><text>gentamicin</text></annotation><annotation id="DDI-MedLine.d89.s2.e1"><infon key="type">drug</infon><location offset="381" length="9"/><text>99mTc-MDP</text></annotation><annotation id="DDI-MedLine.d89.s5.e0"><infon key="type">drug</infon><location offset="848" length="10"/><text>gentamicin</text></annotation><annotation id="DDI-MedLine.d89.s7.e0"><infon key="type">drug</infon><location offset="1090" length="10"/><text>gentamicin</text></annotation><annotation id="DDI-MedLine.d89.s7.e1"><infon key="type">drug</infon><location offset="1142" length="9"/><text>99mTc-MDP</text></annotation><annotation id="DDI-MedLine.d89.s8.e0"><infon key="type">drug</infon><location offset="1290" length="10"/><text>gentamicin</text></annotation><annotation id="DDI-MedLine.d89.s8.e1"><infon key="type">drug</infon><location offset="1338" length="10"/><text>gentamicin</text></annotation></passage></document><document><id>DDI-MedLine.d18</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. Powder x-ray diffraction, differential scanning calorimetry, differential thermal analysis, and scanning electron microscopy were used to characterize the aerosol particles and starting material. No change in phase was detected, although the aerosol particles appeared to contain residual solvent. The dissolution rate of the aerosol particles in saline was low and variable. Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies. Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate. Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. These results show that lung surfactant has the potential of enhancing the rate and extent of dissolution of drugs administered to the lung.</text><annotation id="DDI-MedLine.d18.s0.e0"><infon key="type">drug</infon><location offset="42" length="10"/><text>budesonide</text></annotation><annotation id="DDI-MedLine.d18.s1.e2"><infon key="type">drug</infon><location offset="212" length="10"/><text>budesonide</text></annotation><annotation id="DDI-MedLine.d18.s2.e0"><infon key="type">drug</infon><location offset="260" length="10"/><text>budesonide</text></annotation><annotation id="DDI-MedLine.d18.s2.e1"><infon key="type">drug</infon><location offset="294" length="7"/><text>ethanol</text></annotation><annotation id="DDI-MedLine.d18.s6.e1"><infon key="type">drug</infon><location offset="853" length="10"/><text>budesonide</text></annotation><annotation id="DDI-MedLine.d18.s8.e0"><infon key="type">drug</infon><location offset="1094" length="10"/><text>budesonide</text></annotation><annotation id="DDI-MedLine.d18.s8.e1"><infon key="type">drug</infon><location offset="1182" length="10"/><text>budesonide</text></annotation></passage></document><document><id>DDI-MedLine.d43</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Tumor phenotype and susceptibility to progression as an expression of subpopulations of initiated murine cells.
Currently, it is conceived that a number of events, or hits, are required for the induction of tumors by chemical agents. The first phase of this sequence, initiation, is considered to result from at least one event in the genetic apparatus. Analyses of this sequence, however, usually give little consideration to the nature of the target cell or to the characteristics of the resultant tumors. Vesselinovitch et al. (Cancer Res., 38: 2003-2010, 1978) have reported that a single, small pulse of carcinogen can induce early and numerous liver tumors when administered neonatally to mice with a genetic predisposition to hepatotumorigenesis. In the current study, the nonpredisposed strain C57BL/6N was also shown to be highly susceptible to diethylnitrosamine during the neonatal period. C57BL/6N demonstrated large numbers of two of the three types of liver tumors seen in livers of genetically predisposed mice, one of which required the additional stimulus of dietary phenobarbital for growth. Tumors of more malignant phenotype were demonstrated only in genetically predisposed mice (C57BL/6N X C3H/HeN F1) that received one dose of carcinogen. These findings suggest that the phenotype of a tumor that results from a pulse of a chemical carcinogen may depend upon the target cell. The initiated cells that result from this hit may vary from those that demonstrate very little progression in cell type and may or may not require exogenous enhancement of growth to those that can progress very rapidly to fully malignant behavior. The latter might arise from a hit in a genetically initiated cell, the result of which is a more rapid progression in tumor type.</text><annotation id="DDI-MedLine.d43.s7.e0"><infon key="type">drug</infon><location offset="1084" length="13"/><text>phenobarbital</text></annotation></passage></document><document><id>DDI-MedLine.d53</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.&#xd;
1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. We have shown that MCF-7 cells treated with 100 nM 1,25(OH)2D3 exhibit characteristic apoptotic morphology (pyknotic nuclei, chromatin and cytoplasmic condensation, nuclear matrix protein reorganization) within 48 h. In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone. Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. We have selected a subclone of MCF-7 cells resistant to 1,25(OH)2D3 (MCF-7D3Res). These cells express the vitamin D receptor and exhibit doubling times comparable to the parental MCF-7 cells, even when grown in 100 mM 1,25(OH)2D3. Treatment of both parental and resistant MCF-7 cells with TAM induces apoptosis and clusterin. These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of vitamin-D-mediated signalling or disruption of estrogen-dependent signalling.</text><annotation id="DDI-MedLine.d53.s1.e0"><infon key="type">drug</infon><location offset="93" length="30"/><text>25-Dihydroxycholecalciferol D3</text></annotation><annotation id="DDI-MedLine.d53.s1.e1"><infon key="type">drug</infon><location offset="125" length="11"/><text>1,25(OH)2D3</text></annotation><annotation id="DDI-MedLine.d53.s2.e0"><infon key="type">drug</infon><location offset="304" length="11"/><text>1,25(OH)2D3</text></annotation><annotation id="DDI-MedLine.d53.s3.e0"><infon key="type">drug</infon><location offset="541" length="11"/><text>1,25(OH)2D3</text></annotation><annotation id="DDI-MedLine.d53.s4.e1"><infon key="type">drug</infon><location offset="737" length="11"/><text>1,25(OH)2D3</text></annotation><annotation id="DDI-MedLine.d53.s5.e0"><infon key="type">drug</infon><location offset="780" length="11"/><text>1,25(OH)2D3</text></annotation><annotation id="DDI-MedLine.d53.s6.e0"><infon key="type">drug</infon><location offset="991" length="11"/><text>1,25(OH)2D3</text></annotation><annotation id="DDI-MedLine.d53.s7.e0"><infon key="type">drug</infon><location offset="1153" length="11"/><text>1,25(OH)2D3</text></annotation></passage></document><document><id>DDI-MedLine.d9</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Pharmacokinetics of calcium-entry blockers.
Effective use of drugs in therapy depends not only on clinical acumen but also on the availability of relevant pharmacokinetic and pharmacodynamic data. Such information assists in development of safe dosing regimens, prediction of abnormal handling of drugs in states of disease and disorder and anticipation of drug interactions. For the calcium-entry blocking agents now available in the United States (verapamil, nifedipine and diltiazem), these data appeared well after clinical patterns of use evolved. Nonetheless, their relevance continues to be demonstrated by the dependence of each agent on intact liver blood flow and function for normal rates of elimination; by the nonlinear kinetic characteristics for verapamil and diltiazem (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; and by observations now appearing on the relation between plasma drug levels and drug effects, both therapeutic and toxic. Such data are discussed herein, with emphasis on those aspects that impact on the clinical use of the calcium-entry antagonists.</text><annotation id="DDI-MedLine.d9.s3.e1"><infon key="type">drug</infon><location offset="450" length="9"/><text>verapamil</text></annotation><annotation id="DDI-MedLine.d9.s3.e2"><infon key="type">drug</infon><location offset="461" length="10"/><text>nifedipine</text></annotation><annotation id="DDI-MedLine.d9.s3.e3"><infon key="type">drug</infon><location offset="476" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d9.s5.e0"><infon key="type">drug</infon><location offset="761" length="9"/><text>verapamil</text></annotation><annotation id="DDI-MedLine.d9.s5.e1"><infon key="type">drug</infon><location offset="775" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d9.s5.e2"><infon key="type">drug</infon><location offset="803" length="10"/><text>nifedipine</text></annotation></passage></document><document><id>DDI-MedLine.d54</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Cholinergic role in alcohol's effects on evoked potentials in visual cortex of the albino rat.&#xd;
Photic evoked potentials were recorded from the visual cortex of chronically implanted albino rats. Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of alcohol on these components may help to trace pathways which are affected by alcohol. In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), physostigmine (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. Ethanol depressed the amplitudes of most evoked potential components in comparison to saline administration. Component P2, however, was increased in amplitude. Physostigmine briefly reduced the amplitude of most components, including P2. In contrast, atropine increased the amplitudes of components P1 and P2, while decreasing components N1, N2 and N3 for varying durations of time. Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. Pretreatment with atropine likewise further reduced the amplitudes of components P1 and N1, and produced a similar effect on component N3. Atropine, either alone or in combination with alcohol, produced approximately the same degree of enhancement of component P2. In comparison to saline values, all three agents produced reliable increases in peak latency for most of the components, with only N3 showing no effects. The amplitude data from this study suggest that ethanol's augmentation of component P2 may result, at least in part, from alterations in cholinergic functions.</text><annotation id="DDI-MedLine.d54.s0.e0"><infon key="type">drug</infon><location offset="20" length="7"/><text>alcohol</text></annotation><annotation id="DDI-MedLine.d54.s2.e0"><infon key="type">drug</infon><location offset="347" length="7"/><text>alcohol</text></annotation><annotation id="DDI-MedLine.d54.s2.e1"><infon key="type">drug</infon><location offset="424" length="7"/><text>alcohol</text></annotation><annotation id="DDI-MedLine.d54.s3.e0"><infon key="type">drug</infon><location offset="543" length="7"/><text>ethanol</text></annotation><annotation id="DDI-MedLine.d54.s3.e1"><infon key="type">drug</infon><location offset="563" length="13"/><text>physostigmine</text></annotation><annotation id="DDI-MedLine.d54.s3.e2"><infon key="type">drug</infon><location offset="592" length="8"/><text>atropine</text></annotation><annotation id="DDI-MedLine.d54.s4.e0"><infon key="type">drug</infon><location offset="632" length="7"/><text>Ethanol</text></annotation><annotation id="DDI-MedLine.d54.s6.e0"><infon key="type">drug</infon><location offset="792" length="13"/><text>Physostigmine</text></annotation><annotation id="DDI-MedLine.d54.s7.e0"><infon key="type">drug</infon><location offset="883" length="8"/><text>atropine</text></annotation><annotation id="DDI-MedLine.d54.s8.e0"><infon key="type">drug</infon><location offset="1015" length="13"/><text>Physostigmine</text></annotation><annotation id="DDI-MedLine.d54.s8.e1"><infon key="type">drug</infon><location offset="1077" length="7"/><text>alcohol</text></annotation><annotation id="DDI-MedLine.d54.s8.e2"><infon key="type">drug</infon><location offset="1138" length="7"/><text>alcohol</text></annotation><annotation id="DDI-MedLine.d54.s9.e0"><infon key="type">drug</infon><location offset="1201" length="8"/><text>atropine</text></annotation><annotation id="DDI-MedLine.d54.s10.e0"><infon key="type">drug</infon><location offset="1322" length="8"/><text>Atropine</text></annotation><annotation id="DDI-MedLine.d54.s10.e1"><infon key="type">drug</infon><location offset="1368" length="7"/><text>alcohol</text></annotation><annotation id="DDI-MedLine.d54.s12.e0"><infon key="type">drug</infon><location offset="1650" length="7"/><text>ethanol</text></annotation></passage></document><document><id>DDI-MedLine.d92</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Systemic antibiotic agents.Understanding the breadth of systemic antimicrobial agents available for use by the dermatologist and their associated side-effect profiles and drug interactions allows the clinician to offer patients optimal care in the management of cutaneous infectious disease.</text></passage></document><document><id>DDI-MedLine.d131</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.&#xd;
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. Antinociception was measured by the hot-plate method. It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.</text></passage></document><document><id>DDI-MedLine.d34</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Interactions of cobalt and iron in absorption and retention.&#xd;
The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. Retention was calculated by the balance technique and by the comparative slaughter technique. After one day, fecal as well as urinary excretion of both elements had already responded to the dietary treatments, with constant values being reached after approximately three days. Cobalt excretion was enhanced by supplementary cobalt; fecal excretion, too, was increased by supplementary iron; whereas urinary excretion was decreased in both cases. Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. Consequently, the effect of iron on the retention of cobalt was lower than on absorption. This suggests that interactions between the two elements only take place at the site of absorption. Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. Differences in iron balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further Fe.(ABSTRACT TRUNCATED AT 250 WORDS)</text><annotation id="DDI-MedLine.d34.s0.e0"><infon key="type">drug</infon><location offset="16" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s0.e1"><infon key="type">drug</infon><location offset="27" length="4"/><text>iron</text></annotation><annotation id="DDI-MedLine.d34.s1.e0"><infon key="type">drug</infon><location offset="96" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s1.e1"><infon key="type">drug</infon><location offset="107" length="4"/><text>iron</text></annotation><annotation id="DDI-MedLine.d34.s1.e2"><infon key="type">drug</infon><location offset="333" length="2"/><text>Co</text></annotation><annotation id="DDI-MedLine.d34.s1.e3"><infon key="type">drug</infon><location offset="359" length="2"/><text>Fe</text></annotation><annotation id="DDI-MedLine.d34.s4.e0"><infon key="type">drug</infon><location offset="687" length="6"/><text>Cobalt</text></annotation><annotation id="DDI-MedLine.d34.s4.e1"><infon key="type">drug</infon><location offset="734" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s5.e0"><infon key="type">drug</infon><location offset="795" length="4"/><text>iron</text></annotation><annotation id="DDI-MedLine.d34.s7.e0"><infon key="type">drug</infon><location offset="867" length="4"/><text>iron</text></annotation><annotation id="DDI-MedLine.d34.s7.e1"><infon key="type">drug</infon><location offset="914" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s7.e2"><infon key="type">drug</infon><location offset="937" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s8.e0"><infon key="type">drug</infon><location offset="1016" length="2"/><text>Fe</text></annotation><annotation id="DDI-MedLine.d34.s8.e1"><infon key="type">drug</infon><location offset="1039" length="2"/><text>Fe</text></annotation><annotation id="DDI-MedLine.d34.s8.e2"><infon key="type">drug</infon><location offset="1097" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s9.e0"><infon key="type">drug</infon><location offset="1133" length="4"/><text>iron</text></annotation><annotation id="DDI-MedLine.d34.s9.e1"><infon key="type">drug</infon><location offset="1158" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s11.e0"><infon key="type">drug</infon><location offset="1322" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s11.e1"><infon key="type">drug</infon><location offset="1362" length="4"/><text>iron</text></annotation><annotation id="DDI-MedLine.d34.s11.e2"><infon key="type">drug</infon><location offset="1403" length="6"/><text>cobalt</text></annotation><annotation id="DDI-MedLine.d34.s11.e3"><infon key="type">drug</infon><location offset="1413" length="4"/><text>iron</text></annotation><annotation id="DDI-MedLine.d34.s12.e0"><infon key="type">drug</infon><location offset="1468" length="4"/><text>iron</text></annotation><annotation id="DDI-MedLine.d34.s12.e1"><infon key="type">drug</infon><location offset="1642" length="2"/><text>Fe</text></annotation></passage></document><document><id>DDI-MedLine.d97</id><passage><infon key="type">abstract</infon><offset>0</offset><text>[2 epidemics of arsenical encephalopathy in the treatment of trypanosomiasis, Uganda, 1992-1993] Since 1988, the french non-governmental organisation M  decins Sans Fronti  res is running a control program of human african trypanosomiasis in the district of Moyo, North-Uganda. Between 1988 and 1993, more than 7,000 patients were diagnosed and treated. Since 1988, it has been noted that incidence of melarsoprol reaction had increased systematically between June and October of each year, indicating strong seasonal variation. In 1992 and 1993, two outbreaks of arsenical reactive encephalopathy (ARE) occurred in the sleeping sickness center of Adjumani. The incidence of ARE suddenly exceeded 10% of the patients treated by melarsoprol during August 1992 and September 1993. The onset of 80% of those "epidemic"cases, occurred between the 5th and the 11th day of treatment. Two retrospective studies were conducted in 1992 (75 cases) and in 1993 (51 cases). Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. These observations suggest that exogenous co-factors could be involved in the occurrence of ARE. Recommendations were to avoid administration of diffusible anti-helminthic treatment during the cure, and to improve the general conditions of patients before the cure of melarsoprol.</text><annotation id="DDI-MedLine.d97.s2.e0"><infon key="type">drug</infon><location offset="402" length="11"/><text>melarsoprol</text></annotation><annotation id="DDI-MedLine.d97.s4.e0"><infon key="type">drug</infon><location offset="728" length="11"/><text>melarsoprol</text></annotation><annotation id="DDI-MedLine.d97.s8.e0"><infon key="type">drug</infon><location offset="1054" length="13"/><text>thiabendazole</text></annotation><annotation id="DDI-MedLine.d97.s8.e1"><infon key="type">drug</infon><location offset="1105" length="11"/><text>melarsoprol</text></annotation><annotation id="DDI-MedLine.d97.s10.e1"><infon key="type">drug</infon><location offset="1443" length="11"/><text>melarsoprol</text></annotation></passage></document><document><id>DDI-MedLine.d2</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Failure of neomycin to modify ACTH induced hypertension in sheep.Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. The effects of oral neomycin on ACTH induced hypertension were examined in conscious sheep. Neomycin has no effect on the blood pressure or metabolic responses to ACTH in sheep.</text><annotation id="DDI-MedLine.d2.s0.e0"><infon key="type">drug</infon><location offset="11" length="8"/><text>neomycin</text></annotation><annotation id="DDI-MedLine.d2.s1.e0"><infon key="type">drug</infon><location offset="97" length="8"/><text>neomycin</text></annotation><annotation id="DDI-MedLine.d2.s1.e2"><infon key="type">drug</infon><location offset="206" length="4"/><text>ACTH</text></annotation><annotation id="DDI-MedLine.d2.s2.e0"><infon key="type">drug</infon><location offset="245" length="8"/><text>neomycin</text></annotation><annotation id="DDI-MedLine.d2.s3.e0"><infon key="type">drug</infon><location offset="317" length="8"/><text>Neomycin</text></annotation></passage></document><document><id>DDI-MedLine.d124</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.&#xd;
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures. The authors investigated the possibility of a similar interaction between oxycodone and levofloxacin. Eight healthy volunteers were randomized in an open-label, two-way crossover study to receive oxycodone, 5 mg p.o. Q4H, and levofloxacin, 500 mg p.o. 1 hour after starting the oxycodone or levofloxacin 500 mg p.o. alone. Blood samples were drawn at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours for Cmax, tmax, and AUC determinations. There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens. It was concluded that oral oxycodone and levofloxacin can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.</text><annotation id="DDI-MedLine.d124.s0.e0"><infon key="type">drug</infon><location offset="28" length="12"/><text>levofloxacin</text></annotation><annotation id="DDI-MedLine.d124.s0.e1"><infon key="type">drug</infon><location offset="45" length="9"/><text>oxycodone</text></annotation><annotation id="DDI-MedLine.d124.s1.e0"><infon key="type">drug</infon><location offset="186" length="13"/><text>trovafloxacin</text></annotation><annotation id="DDI-MedLine.d124.s1.e1"><infon key="type">drug</infon><location offset="204" length="13"/><text>ciprofloxacin</text></annotation><annotation id="DDI-MedLine.d124.s1.e3"><infon key="type">drug</infon><location offset="285" length="8"/><text>morphine</text></annotation><annotation id="DDI-MedLine.d124.s2.e0"><infon key="type">drug</infon><location offset="362" length="13"/><text>trovafloxacin</text></annotation><annotation id="DDI-MedLine.d124.s2.e1"><infon key="type">drug</infon><location offset="380" length="13"/><text>ciprofloxacin</text></annotation><annotation id="DDI-MedLine.d124.s3.e0"><infon key="type">drug</infon><location offset="520" length="9"/><text>oxycodone</text></annotation><annotation id="DDI-MedLine.d124.s3.e1"><infon key="type">drug</infon><location offset="534" length="12"/><text>levofloxacin</text></annotation><annotation id="DDI-MedLine.d124.s4.e0"><infon key="type">drug</infon><location offset="642" length="9"/><text>oxycodone</text></annotation><annotation id="DDI-MedLine.d124.s5.e0"><infon key="type">drug</infon><location offset="672" length="12"/><text>levofloxacin</text></annotation><annotation id="DDI-MedLine.d124.s6.e0"><infon key="type">drug</infon><location offset="724" length="9"/><text>oxycodone</text></annotation><annotation id="DDI-MedLine.d124.s6.e1"><infon key="type">drug</infon><location offset="737" length="12"/><text>levofloxacin</text></annotation><annotation id="DDI-MedLine.d124.s9.e0"><infon key="type">drug</infon><location offset="1062" length="12"/><text>levofloxacin</text></annotation><annotation id="DDI-MedLine.d124.s9.e1"><infon key="type">drug</infon><location offset="1082" length="12"/><text>levofloxacin</text></annotation><annotation id="DDI-MedLine.d124.s9.e2"><infon key="type">drug</infon><location offset="1095" length="9"/><text>oxycodone</text></annotation><annotation id="DDI-MedLine.d124.s10.e0"><infon key="type">drug</infon><location offset="1142" length="9"/><text>oxycodone</text></annotation><annotation id="DDI-MedLine.d124.s10.e1"><infon key="type">drug</infon><location offset="1156" length="12"/><text>levofloxacin</text></annotation></passage></document><document><id>DDI-MedLine.d83</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Olanzapine: an updated review of its use in the management of schizophrenia.
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. Compared with conventional antipsychotics, it has greater affinity for serotonin 5-HT2A than for dopamine D2 receptors. In large, well controlled trials in patients with schizophrenia or related psychoses, olanzapine 5 to 20 mg/day was significantly superior to haloperidol 5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. The 1-year risk of relapse (rehospitalisation) was significantly lower with olanzapine than with haloperidol treatment. In the first double-blind comparative study (28-week) of olanzapine and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. In contrast, preliminary results from an 8-week controlled study suggested risperidone 2 to 6 mg/day was superior to olanzapine 5 to 20 mg/day against positive and anxiety/depressive symptoms (p &lt; 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either risperidone or haloperidol. However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of olanzapine and risperidone treatment in patients with schizophrenia or schizoaffective disorder. Several studies indicate that olanzapine has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of olanzapine in the treatment of depressive symptomatology. Olanzapine is associated with significantly fewer extrapyramidal symptoms than haloperidol and risperidone. In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. The most common adverse effects reported with olanzapine are bodyweight gain, somnolence, dizziness, anticholinergic effects (constipation and dry mouth) and transient asymptomatic liver enzyme elevations. In comparison with haloperidol, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. The high acquisition cost of olanzapine is offset by reductions in other treatment costs (inpatient and/or outpatient services) of schizophrenia. Pharmacoeconomic analyses indicate that olanzapine does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with haloperidol. Compared with risperidone, olanzapine has also been reported to decrease overall treatment costs, despite the several-fold higher daily acquisition cost of the drug. Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as risperidone. CONCLUSIONS: Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.</text><annotation id="DDI-MedLine.d83.s0.e0"><infon key="type">drug</infon><location offset="0" length="10"/><text>Olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s1.e0"><infon key="type">drug</infon><location offset="77" length="10"/><text>Olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s3.e0"><infon key="type">drug</infon><location offset="471" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s3.e1"><infon key="type">drug</infon><location offset="527" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s4.e0"><infon key="type">drug</infon><location offset="807" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s4.e1"><infon key="type">drug</infon><location offset="828" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s5.e0"><infon key="type">drug</infon><location offset="908" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s5.e1"><infon key="type">drug</infon><location offset="923" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s5.e2"><infon key="type">drug</infon><location offset="936" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s5.e3"><infon key="type">drug</infon><location offset="1010" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s6.e0"><infon key="type">drug</infon><location offset="1210" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s6.e1"><infon key="type">drug</infon><location offset="1252" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s7.e0"><infon key="type">drug</infon><location offset="1516" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s7.e1"><infon key="type">drug</infon><location offset="1667" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s7.e2"><infon key="type">drug</infon><location offset="1682" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s8.e0"><infon key="type">drug</infon><location offset="1794" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s8.e1"><infon key="type">drug</infon><location offset="1809" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s9.e0"><infon key="type">drug</infon><location offset="1921" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s9.e1"><infon key="type">drug</infon><location offset="2049" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s10.e0"><infon key="type">drug</infon><location offset="2107" length="10"/><text>Olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s10.e1"><infon key="type">drug</infon><location offset="2186" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s10.e2"><infon key="type">drug</infon><location offset="2202" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s11.e0"><infon key="type">drug</infon><location offset="2228" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s11.e1"><infon key="type">drug</infon><location offset="2301" length="9"/><text>clozapine</text></annotation><annotation id="DDI-MedLine.d83.s11.e2"><infon key="type">drug</infon><location offset="2370" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s12.e0"><infon key="type">drug</infon><location offset="2464" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s13.e0"><infon key="type">drug</infon><location offset="2643" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s13.e1"><infon key="type">drug</infon><location offset="2719" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s13.e2"><infon key="type">drug</infon><location offset="2830" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s13.e3"><infon key="type">drug</infon><location offset="2908" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s14.e0"><infon key="type">drug</infon><location offset="2949" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s15.e0"><infon key="type">drug</infon><location offset="3106" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s15.e1"><infon key="type">drug</infon><location offset="3240" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s16.e0"><infon key="type">drug</infon><location offset="3267" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s16.e1"><infon key="type">drug</infon><location offset="3280" length="10"/><text>olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s17.e0"><infon key="type">drug</infon><location offset="3419" length="10"/><text>Olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s17.e1"><infon key="type">drug</infon><location offset="3543" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s17.e2"><infon key="type">drug</infon><location offset="3590" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s18.e0"><infon key="type">drug</infon><location offset="3616" length="10"/><text>Olanzapine</text></annotation><annotation id="DDI-MedLine.d83.s18.e1"><infon key="type">drug</infon><location offset="3686" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s19.e0"><infon key="type">drug</infon><location offset="3917" length="11"/><text>haloperidol</text></annotation><annotation id="DDI-MedLine.d83.s19.e1"><infon key="type">drug</infon><location offset="3933" length="11"/><text>risperidone</text></annotation><annotation id="DDI-MedLine.d83.s19.e2"><infon key="type">drug</infon><location offset="4020" length="10"/><text>olanzapine</text></annotation></passage></document><document><id>DDI-MedLine.d86</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.&#xd;
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists. METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together. The three study periods were separated by a 21-day washout phase. RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.</text><annotation id="DDI-MedLine.d86.s0.e0"><infon key="type">drug</infon><location offset="57" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s0.e1"><infon key="type">drug</infon><location offset="71" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s1.e0"><infon key="type">drug</infon><location offset="165" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s1.e3"><infon key="type">drug</infon><location offset="261" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s3.e0"><infon key="type">drug</infon><location offset="658" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s3.e1"><infon key="type">drug</infon><location offset="698" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s5.e0"><infon key="type">drug</infon><location offset="875" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s5.e1"><infon key="type">drug</infon><location offset="1062" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s5.e2"><infon key="type">drug</infon><location offset="1132" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s6.e0"><infon key="type">drug</infon><location offset="1237" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s6.e1"><infon key="type">drug</infon><location offset="1294" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s6.e2"><infon key="type">drug</infon><location offset="1319" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s7.e0"><infon key="type">drug</infon><location offset="1417" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s7.e3"><infon key="type">drug</infon><location offset="1512" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s7.e4"><infon key="type">drug</infon><location offset="1561" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s8.e0"><infon key="type">drug</infon><location offset="1688" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s8.e1"><infon key="type">drug</infon><location offset="1731" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s8.e2"><infon key="type">drug</infon><location offset="1808" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s9.e0"><infon key="type">drug</infon><location offset="1891" length="9"/><text>sirolimus</text></annotation><annotation id="DDI-MedLine.d86.s9.e1"><infon key="type">drug</infon><location offset="1901" length="9"/><text>diltiazem</text></annotation><annotation id="DDI-MedLine.d86.s9.e2"><infon key="type">drug</infon><location offset="1936" length="9"/><text>sirolimus</text></annotation></passage></document><document><id>DDI-MedLine.d66</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Changes in urinary homocysteine following synthetic steroidal estrogen and progestogen administration to rats.The present work involved the administration of both ethynyl estradiol and levonorgestrel to groups of rats, followed by determination of the homocysteine excretion rate in urine. The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and levonorgestrel-treated rats and the levels shown by rats treated with ethynyl estradiol. The implications of these results are discussed, especially with respect to observations which indicate that homocysteine may be a precipitating factor in the development of thrombosis. Also included in this paper is a study which confirms the identity of the HPLC peak as being homocysteine by forming a radioactive derivative of this particular sulphydryl-containing amino acid, and then analysing the resulting mixture by TLC.</text><annotation id="DDI-MedLine.d66.s1.e0"><infon key="type">drug</infon><location offset="163" length="17"/><text>ethynyl estradiol</text></annotation><annotation id="DDI-MedLine.d66.s1.e1"><infon key="type">drug</infon><location offset="185" length="14"/><text>levonorgestrel</text></annotation><annotation id="DDI-MedLine.d66.s2.e0"><infon key="type">drug</infon><location offset="439" length="14"/><text>levonorgestrel</text></annotation><annotation id="DDI-MedLine.d66.s2.e1"><infon key="type">drug</infon><location offset="509" length="17"/><text>ethynyl estradiol</text></annotation></passage></document><document><id>DDI-MedLine.d7</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Enhanced theophylline clearance secondary to phenytoin therapy.&#xd;
This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. Maximum calculated theophylline clearance ranged from 2 1/2 to 3 1/2 times baseline. Onset of the interaction began within five days of beginning concurrent therapy. With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.</text><annotation id="DDI-MedLine.d7.s0.e0"><infon key="type">drug</infon><location offset="9" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d7.s0.e1"><infon key="type">drug</infon><location offset="45" length="9"/><text>phenytoin</text></annotation><annotation id="DDI-MedLine.d7.s1.e0"><infon key="type">drug</infon><location offset="106" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d7.s1.e1"><infon key="type">drug</infon><location offset="167" length="9"/><text>phenytoin</text></annotation><annotation id="DDI-MedLine.d7.s2.e0"><infon key="type">drug</infon><location offset="212" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d7.s4.e0"><infon key="type">drug</infon><location offset="411" length="9"/><text>phenytoin</text></annotation><annotation id="DDI-MedLine.d7.s4.e1"><infon key="type">drug</infon><location offset="516" length="12"/><text>theophylline</text></annotation></passage></document><document><id>DDI-MedLine.d51</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors.&#xd;
We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. All antagonists decreased the time spent in the light zone in this test, which suggested that these compounds have anxiogenic effects. The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. Finally, it is notable that xanthine-derived adenosine antagonists tested here commonly showed anxiogenic effects in the light/dark test in mice. It is suggested that there is a minor contribution of adenosine receptors to these effects, although theophylline-induced anxiogenic effects were antagonized by an A2 receptor agonist.</text><annotation id="DDI-MedLine.d51.s1.e0"><infon key="type">drug</infon><location offset="170" length="8"/><text>caffeine</text></annotation><annotation id="DDI-MedLine.d51.s1.e1"><infon key="type">drug</infon><location offset="180" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d51.s3.e0"><infon key="type">drug</infon><location offset="455" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d51.s4.e0"><infon key="type">drug</infon><location offset="636" length="12"/><text>theophylline</text></annotation><annotation id="DDI-MedLine.d51.s4.e3"><infon key="type">drug</infon><location offset="805" length="9"/><text>CGS 21680</text></annotation><annotation id="DDI-MedLine.d51.s6.e0"><infon key="type">drug</infon><location offset="1074" length="12"/><text>theophylline</text></annotation></passage></document><document><id>DDI-MedLine.d3</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). Twenty-four healthy male subjects were randomized to one of two cohorts. All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. Rifabutin did not significantly affect amprenavir's pharmacokinetics. Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. Amprenavir decreased the results of the ERMBT by 83%. The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. Amprenavir plus rifampin was well tolerated. Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.</text><annotation id="DDI-MedLine.d3.s0.e0"><infon key="type">drug</infon><location offset="36" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s0.e1"><infon key="type">drug</infon><location offset="51" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s0.e2"><infon key="type">drug</infon><location offset="64" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s1.e0"><infon key="type">drug</infon><location offset="183" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s1.e1"><infon key="type">drug</infon><location offset="208" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s1.e2"><infon key="type">drug</infon><location offset="221" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s3.e0"><infon key="type">drug</infon><location offset="410" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s3.e1"><infon key="type">drug</infon><location offset="511" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s3.e2"><infon key="type">drug</infon><location offset="560" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s4.e0"><infon key="type">drug</infon><location offset="628" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s4.e1"><infon key="type">drug</infon><location offset="644" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s4.e2"><infon key="type">drug</infon><location offset="689" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s4.e3"><infon key="type">drug</infon><location offset="705" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s5.e0"><infon key="type">drug</infon><location offset="777" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s5.e1"><infon key="type">drug</infon><location offset="789" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s5.e2"><infon key="type">drug</infon><location offset="804" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s6.e0"><infon key="type">drug</infon><location offset="908" length="9"/><text>Rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s6.e1"><infon key="type">drug</infon><location offset="947" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s7.e0"><infon key="type">drug</infon><location offset="978" length="10"/><text>Amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s7.e1"><infon key="type">drug</infon><location offset="1067" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s8.e0"><infon key="type">drug</infon><location offset="1147" length="8"/><text>Rifampin</text></annotation><annotation id="DDI-MedLine.d3.s8.e1"><infon key="type">drug</infon><location offset="1195" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s8.e2"><infon key="type">drug</infon><location offset="1218" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s8.e3"><infon key="type">drug</infon><location offset="1246" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s9.e0"><infon key="type">drug</infon><location offset="1273" length="10"/><text>Amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s10.e0"><infon key="type">drug</infon><location offset="1369" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s10.e1"><infon key="type">drug</infon><location offset="1383" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s11.e0"><infon key="type">drug</infon><location offset="1443" length="10"/><text>Amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s11.e1"><infon key="type">drug</infon><location offset="1459" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s12.e0"><infon key="type">drug</infon><location offset="1488" length="10"/><text>Amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s12.e1"><infon key="type">drug</infon><location offset="1504" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s13.e0"><infon key="type">drug</infon><location offset="1579" length="8"/><text>Rifampin</text></annotation><annotation id="DDI-MedLine.d3.s13.e1"><infon key="type">drug</infon><location offset="1634" length="10"/><text>amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s14.e0"><infon key="type">drug</infon><location offset="1687" length="10"/><text>Amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s14.e1"><infon key="type">drug</infon><location offset="1735" length="9"/><text>rifabutin</text></annotation><annotation id="DDI-MedLine.d3.s15.e0"><infon key="type">drug</infon><location offset="1815" length="10"/><text>Amprenavir</text></annotation><annotation id="DDI-MedLine.d3.s15.e1"><infon key="type">drug</infon><location offset="1850" length="8"/><text>rifampin</text></annotation><annotation id="DDI-MedLine.d3.s15.e2"><infon key="type">drug</infon><location offset="1863" length="9"/><text>rifabutin</text></annotation></passage></document><document><id>DDI-MedLine.d75</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Interference of biocytin with opioid-evoked hyperpolarization and membrane properties of rat spinal substantia gelatinosa neurons.In our laboratory, preliminary whole-cell, tight seal recordings of rat spinal substantia gelatinosa neurons including biocytin in the patch pipette yielded a significantly smaller proportion of neurons hyperpolarized by selective opioid agonists compared with recordings without biocytin. Therefore, we investigated the effects of biocytin inclusion on opioid responses and other membrane properties during whole-cell, tight seal recordings of these neurons. The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not &lt; or =0.2% biocytin was included in the recording pipette, compared with neurons recorded without biocytin. However, a significantly higher proportion of neurons fired spontaneous action potentials with either 0.05-0.2 or 1% biocytin compared to no biocytin. Resting membrane potential, input impedance and the proportion of neurons displaying transient outward rectification were each significantly altered for neurons recorded with 1% but not 0.05-0.2% biocytin. These effects may be due to a relatively specific blockade of diverse potassium channel types. Because efficient labeling can be achieved with 0.1% biocytin with whole-cell recording, higher concentrations are contraindicated.</text></passage></document><document><id>DDI-MedLine.d121</id><passage><infon key="type">abstract</infon><offset>0</offset><text>[Hippocampus as interaction sites between cerebral memory systems]
Most of the current theories assume that there are multiple forms of memory that are supported by separate brain systems and have different characteristics. Animals studies on the various dual-memory theories have been carried out mainly on the basis of hippocampal system function. Specifically, they have focused on aspects of learning and memory that are impaired (vs. spared) by lesions of the hippocampal formation. However, there are several instances in the animal literature showing that hippocampal lesions actually produced enhanced learning and memory function. Moreover, the acquisition of tasks that are facilitated by hippocampal lesions (or dysfunction) is nevertheless associated, in intact subjects, with specific neurobiological alterations in the hippocampus. This problem has been analysed using two different tasks in mice: a bar-press conditioning and a spatial discrimination task. Results showed that, depending on the task considered, the same pharmacological treatment produced either a facilitation or an impairment of acquisition. Moreover, each task induced significant alterations in hippocampal adenylate cyclase activity but in opposite directions. Together with previous findings, these results suggest that the hippocampus is involved in both the so-called "hippocampal-dependent""hippocampal-independent" forms of memory. It is postulated that some of the observed training-induced neurobiological alterations might reflect the interaction between two (or more) competing memory systems at the hippocampal level. Thus, in addition to its proposed specific information processing functions (i.e., relational), the hippocampus would play a role in addressing information to the brain memory system that, in a given situation, has the best adaptive value.(ABSTRACT TRUNCATED AT 250 WORDS)</text></passage></document><document><id>DDI-MedLine.d14</id><passage><infon key="type">abstract</infon><offset>0</offset><text>[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion] Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. It was established that both angiotensins inhibited gastric acid secretion stimulated by pentagastrin but not by histamine. Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of angiotensins suggested the mediation of angiotensin influence through the modulation of cholinergic reactions of parietal cells in the stomach.</text><annotation id="DDI-MedLine.d14.s0.e3"><infon key="type">drug</infon><location offset="218" length="12"/><text>pentagastrin</text></annotation><annotation id="DDI-MedLine.d14.s0.e4"><infon key="type">drug</infon><location offset="236" length="9"/><text>histamine</text></annotation><annotation id="DDI-MedLine.d14.s1.e0"><infon key="type">drug</infon><location offset="367" length="12"/><text>pentagastrin</text></annotation><annotation id="DDI-MedLine.d14.s1.e1"><infon key="type">drug</infon><location offset="391" length="9"/><text>histamine</text></annotation></passage></document><document><id>DDI-MedLine.d68</id><passage><infon key="type">abstract</infon><offset>0</offset><text>[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. The higher verografine and iodamide excretion was due to their increased renal tubular secretion. In dogs, cimetidine unchanged the secretion of cardiotrast, a test agent for anionic transport. Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.</text><annotation id="DDI-MedLine.d68.s0.e0"><infon key="type">drug</infon><location offset="15" length="10"/><text>cimetidine</text></annotation><annotation id="DDI-MedLine.d68.s0.e1"><infon key="type">drug</infon><location offset="52" length="10"/><text>verografin</text></annotation><annotation id="DDI-MedLine.d68.s0.e2"><infon key="type">drug</infon><location offset="67" length="8"/><text>iodamide</text></annotation><annotation id="DDI-MedLine.d68.s0.e3"><infon key="type">drug</infon><location offset="114" length="10"/><text>cimetidine</text></annotation><annotation id="DDI-MedLine.d68.s0.e4"><infon key="type">drug</infon><location offset="156" length="11"/><text>verografine</text></annotation><annotation id="DDI-MedLine.d68.s0.e5"><infon key="type">drug</infon><location offset="172" length="8"/><text>iodamide</text></annotation><annotation id="DDI-MedLine.d68.s1.e0"><infon key="type">drug</infon><location offset="233" length="11"/><text>verografine</text></annotation><annotation id="DDI-MedLine.d68.s1.e1"><infon key="type">drug</infon><location offset="249" length="8"/><text>iodamide</text></annotation><annotation id="DDI-MedLine.d68.s2.e0"><infon key="type">drug</infon><location offset="329" length="10"/><text>cimetidine</text></annotation><annotation id="DDI-MedLine.d68.s2.e1"><infon key="type">drug</infon><location offset="367" length="11"/><text>cardiotrast</text></annotation><annotation id="DDI-MedLine.d68.s3.e0"><infon key="type">drug</infon><location offset="460" length="10"/><text>cimetidine</text></annotation><annotation id="DDI-MedLine.d68.s3.e1"><infon key="type">drug</infon><location offset="474" length="11"/><text>verografine</text></annotation><annotation id="DDI-MedLine.d68.s3.e2"><infon key="type">drug</infon><location offset="490" length="8"/><text>iodamide</text></annotation></passage></document><document><id>DDI-MedLine.d30</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Stereoselective behavioral effects of N-allylnormetazocine in pigeons and squirrel monkeys.&#xd;
The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. Intermediate doses of (+)-NANM or PCP produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons; higher doses decreased FI and FR responding in both species. In contrast to its enantiomer, (-)-NANM failed to increase FI responding significantly in either species; at high doses, (-)-NANM decreased FI and FR responding. In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. In pigeons, naloxone did not systematically alter the effects of (-)-NANM, (+)-NANM or PCP. Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. The results demonstrate a high degree of stereoselectivity in the behavioral effects of NANM. The levorotatory isomer had opioid-antagonist and non-opioid agonist effects in pigeons and mixed opioid agonist-antagonist effects in monkeys. The dextrorotatory isomer, on the other hand, had effects similar to those of PCP in both species.</text><annotation id="DDI-MedLine.d30.s7.e2"><infon key="type">drug</infon><location offset="957" length="8"/><text>morphine</text></annotation><annotation id="DDI-MedLine.d30.s8.e3"><infon key="type">drug</infon><location offset="1073" length="8"/><text>naloxone</text></annotation><annotation id="DDI-MedLine.d30.s9.e0"><infon key="type">drug</infon><location offset="1096" length="8"/><text>naloxone</text></annotation><annotation id="DDI-MedLine.d30.s9.e2"><infon key="type">drug</infon><location offset="1233" length="8"/><text>morphine</text></annotation><annotation id="DDI-MedLine.d30.s10.e0"><infon key="type">drug</infon><location offset="1255" length="8"/><text>naloxone</text></annotation><annotation id="DDI-MedLine.d30.s11.e0"><infon key="type">drug</infon><location offset="1335" length="11"/><text>Haloperidol</text></annotation></passage></document><document><id>DDI-MedLine.d102</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Influence of estradiol and progesterone on the sensitivity of rat thoracic aorta to noradrenaline.&#xd;
The aim of this study was to investigate the effects of low and high doses of estradiol, and of progesterone on the response to noradrenaline in rat thoracic aorta. Two weeks after bilateral ovariectomy, female rats received a s.c. injection of vehicle (corn oil, 0.1 mL/day), estradiol (10 microg/kg/day or 4 mg/kg/day) and/or progesterone (20 mg/kg/day), for eight days. On the ninth day, the rats were sacrificed and aortic rings, with or without endothelium, were used to generate concentration-response curves to noradrenaline. Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). There were no significant differences among the pD2 values for noradrenaline in aortic rings without endothelium. Both of these effects were endothelium-dependent.</text><annotation id="DDI-MedLine.d102.s0.e0"><infon key="type">drug</infon><location offset="13" length="9"/><text>estradiol</text></annotation><annotation id="DDI-MedLine.d102.s0.e1"><infon key="type">drug</infon><location offset="27" length="12"/><text>progesterone</text></annotation><annotation id="DDI-MedLine.d102.s0.e2"><infon key="type">drug</infon><location offset="84" length="13"/><text>noradrenaline</text></annotation><annotation id="DDI-MedLine.d102.s1.e0"><infon key="type">drug</infon><location offset="178" length="9"/><text>estradiol</text></annotation><annotation id="DDI-MedLine.d102.s1.e1"><infon key="type">drug</infon><location offset="196" length="12"/><text>progesterone</text></annotation><annotation id="DDI-MedLine.d102.s1.e2"><infon key="type">drug</infon><location offset="228" length="13"/><text>noradrenaline</text></annotation><annotation id="DDI-MedLine.d102.s3.e0"><infon key="type">drug</infon><location offset="377" length="9"/><text>estradiol</text></annotation><annotation id="DDI-MedLine.d102.s3.e1"><infon key="type">drug</infon><location offset="428" length="12"/><text>progesterone</text></annotation><annotation id="DDI-MedLine.d102.s4.e0"><infon key="type">drug</infon><location offset="618" length="13"/><text>noradrenaline</text></annotation><annotation id="DDI-MedLine.d102.s5.e0"><infon key="type">drug</infon><location offset="703" length="9"/><text>estradiol</text></annotation><annotation id="DDI-MedLine.d102.s5.e1"><infon key="type">drug</infon><location offset="742" length="13"/><text>noradrenaline</text></annotation><annotation id="DDI-MedLine.d102.s6.e0"><infon key="type">drug</infon><location offset="941" length="9"/><text>estradiol</text></annotation><annotation id="DDI-MedLine.d102.s6.e1"><infon key="type">drug</infon><location offset="979" length="13"/><text>noradrenaline</text></annotation><annotation id="DDI-MedLine.d102.s6.e2"><infon key="type">drug</infon><location offset="1020" length="12"/><text>progesterone</text></annotation><annotation id="DDI-MedLine.d102.s6.e3"><infon key="type">drug</infon><location offset="1038" length="12"/><text>progesterone</text></annotation><annotation id="DDI-MedLine.d102.s6.e4"><infon key="type">drug</infon><location offset="1058" length="9"/><text>estradiol</text></annotation><annotation id="DDI-MedLine.d102.s7.e0"><infon key="type">drug</infon><location offset="1228" length="13"/><text>noradrenaline</text></annotation></passage></document><document><id>DDI-MedLine.d48</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Modification of surface histidine residues abolishes the cytotoxic activity of Clostridium difficile toxin A.&#xd;
Clostridium difficile toxin A displays both cytotoxic and enterotoxic activities. It has recently been demonstrated that toxin A exerts its cytotoxic effect by the glucosylation of the small GTP-binding proteins of the Rho family. Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A. Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules. The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment. These data suggest the modified histidine residues on toxin A are critical to its cytotoxic activity. Histidine modification had no effect on the glucosyl transferase enzyme activity of toxin A. However, modification abolished the 'cold' binding of toxin to bovine thyroglobulin in an ELISA and reduced ligand binding activity in a rabbit erythrocyte haemagglutination assay. The data suggest that the histidine residues may be crucial to the receptor-binding activity of toxin A. Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.</text><annotation id="DDI-MedLine.d48.s11.e1"><infon key="type">drug</infon><location offset="1346" length="4"/><text>zinc</text></annotation><annotation id="DDI-MedLine.d48.s11.e3"><infon key="type">drug</infon><location offset="1462" length="4"/><text>zinc</text></annotation></passage></document><document><id>DDI-MedLine.d140</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.&#xd;
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. Everolimus dose-proportionality and stability over time were assessed in the context of linear regression and ANOVA models. Everolimus exposure-response relationships between area under the blood concentration-time curve (AUC) and changes in platelets, leukocytes, and lipids were explored with the median-effect model. Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. RESULTS: Everolimus steady state was reached on or before day 7, with a median 3-fold accumulation of drug exposure compared with that after the first postoperative dose. Both steady-state maximum concentration and AUC were dose proportional over the full dose range when assessed on day 1, as well as for the full duration of the study at steady state. There was evidence for longitudinal stability in AUC of everolimus during the course of the study. The interindividual pharmacokinetic variability for AUC was 85.4% and intraindividual, interoccasion variability was 40.8%. Age (range, 17-69 years), weight (range, 49-106 kg), and sex (65 men and 36 women) were not significant contributors to variability. There was an increasing incidence of transient thrombocytopenia (or =100 x 10(9)/L) with increasing everolimus AUC (P = .03). Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). CONCLUSIONS: Everolimus exhibited dose-proportional, stable exposure during the first post-transplant year. For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.</text><annotation id="DDI-MedLine.d140.s0.e0"><infon key="type">drug</infon><location offset="27" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s0.e1"><infon key="type">drug</infon><location offset="182" length="12"/><text>cyclosporine</text></annotation><annotation id="DDI-MedLine.d140.s1.e0"><infon key="type">drug</infon><location offset="279" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s1.e1"><infon key="type">drug</infon><location offset="294" length="12"/><text>cyclosporine</text></annotation><annotation id="DDI-MedLine.d140.s1.e2"><infon key="type">drug</infon><location offset="313" length="11"/><text>ciclosporin</text></annotation><annotation id="DDI-MedLine.d140.s2.e0"><infon key="type">drug</infon><location offset="557" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s2.e1"><infon key="type">drug</infon><location offset="627" length="12"/><text>cyclosporine</text></annotation><annotation id="DDI-MedLine.d140.s2.e2"><infon key="type">drug</infon><location offset="644" length="10"/><text>prednisone</text></annotation><annotation id="DDI-MedLine.d140.s3.e0"><infon key="type">drug</infon><location offset="699" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s3.e1"><infon key="type">drug</infon><location offset="714" length="12"/><text>cyclosporine</text></annotation><annotation id="DDI-MedLine.d140.s4.e0"><infon key="type">drug</infon><location offset="810" length="10"/><text>Everolimus</text></annotation><annotation id="DDI-MedLine.d140.s5.e0"><infon key="type">drug</infon><location offset="934" length="10"/><text>Everolimus</text></annotation><annotation id="DDI-MedLine.d140.s6.e0"><infon key="type">drug</infon><location offset="1155" length="12"/><text>cyclosporine</text></annotation><annotation id="DDI-MedLine.d140.s6.e1"><infon key="type">drug</infon><location offset="1219" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s7.e0"><infon key="type">drug</infon><location offset="1287" length="10"/><text>Everolimus</text></annotation><annotation id="DDI-MedLine.d140.s9.e0"><infon key="type">drug</infon><location offset="1688" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s12.e0"><infon key="type">drug</infon><location offset="2088" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s13.e0"><infon key="type">drug</infon><location offset="2114" length="12"/><text>Cyclosporine</text></annotation><annotation id="DDI-MedLine.d140.s13.e1"><infon key="type">drug</infon><location offset="2266" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s14.e0"><infon key="type">drug</infon><location offset="2340" length="10"/><text>Everolimus</text></annotation><annotation id="DDI-MedLine.d140.s15.e0"><infon key="type">drug</infon><location offset="2457" length="10"/><text>everolimus</text></annotation><annotation id="DDI-MedLine.d140.s15.e1"><infon key="type">drug</infon><location offset="2512" length="12"/><text>cyclosporine</text></annotation></passage></document><document><id>DDI-MedLine.d123</id><passage><infon key="type">abstract</infon><offset>0</offset><text>Vancomycin resistance reversal in enterococci by flavonoids.
The development of clinical vancomycin-resistant strains of enterococci (VRE) is a major cause for concern. Here we show that a combination of galangin or 3,7-dihydroxyflavone with vancomycin may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains. Minimum inhibitory concentrations (MICs) and viable counts were determined in Iso-sensitest broth using a microtitre method. MICs of vancomycin against 67% of resistant clinical isolates and a type strain of enterococci were lowered from > 250 microg mL(-1) to 14 microg mL(-1) in the presence of galangin (12.5 microg mL(-1)) or 3,7-dihydroxyflavone (6.25 microg mL(-1)). Viable counts for type culture E. faecalis ATCC 51299 showed the flavonoids alone significantly lowered numbers of colony forming units (CFUs). CFUs were maintained at low levels (10(3) CFU mL(-1)) for 24 h by vancomycin/flavone combinations. This combinational action in reversing vancomycin resistance of enterococci highlights novel drug targets and has importance in the design of new therapeutic regimes against resistant pathogens.</text><annotation id="DDI-MedLine.d123.s2.e0"><infon key="type">drug</infon><location offset="204" length="8"/><text>galangin</text></annotation><annotation id="DDI-MedLine.d123.s2.e1"><infon key="type">drug</infon><location offset="242" length="10"/><text>vancomycin</text></annotation><annotation id="DDI-MedLine.d123.s4.e0"><infon key="type">drug</infon><location offset="525" length="10"/><text>vancomycin</text></annotation><annotation id="DDI-MedLine.d123.s5.e0"><infon key="type">drug</infon><location offset="689" length="8"/><text>galangin</text></annotation><annotation id="DDI-MedLine.d123.s8.e0"><infon key="type">drug</infon><location offset="975" length="10"/><text>vancomycin</text></annotation></passage></document></collection>